Manhattan Scientifics (MHTX) stock price, revenue, and financials

Manhattan Scientifics market cap is $7.8 m, and annual revenue was $97 k in FY 2019

$7.8 M

MHTX Mkt cap, 16-Oct-2020

$50 K

Manhattan Scientifics Revenue Q2, 2020
Manhattan Scientifics Net income (Q2, 2020)528 K
Manhattan Scientifics EBIT (Q2, 2020)-128 K
Manhattan Scientifics Cash, 30-Jun-2020459 K

Manhattan Scientifics Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

687.0k693.0k652.0k642.0k64.0k150.0k142.0k97.0k

Cost of goods sold

112.0k189.0k7.0k

Gross profit

575.0k693.0k(47.0k)

Gross profit Margin, %

84%100%(33%)

R&D expense

204.0k274.0k960.0k1.9m2.9m3.3m175.0k52.0k8.0k

General and administrative expense

2.5m2.1m1.5m2.3m3.4m3.2m2.1m1.4m1.1m

Operating expense total

2.7m2.3m2.5m4.1m6.3m6.5m2.2m1.4m1.1m

EBIT

(2.2m)(1.6m)(1.8m)(3.5m)(6.3m)(6.4m)(2.3m)(1.4m)(1.0m)

EBIT margin, %

(316%)(238%)(277%)(541%)(9767%)(4255%)(1604%)(1057%)

Interest expense

117.0k473.0k5.0k

Pre tax profit

(2.3m)(1.2m)

Income tax expense

Net Income

(2.3m)(2.1m)(1.9m)(3.8m)8.0m(6.1m)1.5m(8.3m)(1.2m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

172.0k171.0k171.0k172.0k173.0k444.0k191.0k17.0k180.0k150.0k158.0k33.0k4.0k1.0k107.0k42.0k41.0k59.0k50.0k22.0k50.0k

Cost of goods sold

28.0k28.0k3.0k4.0k

Gross profit

144.0k143.0k

Gross profit Margin, %

84%84%

R&D expense

23.0k32.0k396.0k475.0k542.0k554.0k626.0k757.0k962.0k1.0m589.0k824.0k658.0k11.0k31.0k21.0k1.0k2.0k3.0k3.0k2.0k

General and administrative expense

581.0k1.2m602.0k576.0k518.0k346.0k693.0k2.9m860.0k649.0k300.0k779.0k1.3m1.0m813.0k1.0m698.0k776.0k367.0k317.0k395.0k373.0k322.0k220.0k538.0k187.0k169.0k176.0k

Operating expense total

581.0k1.2m602.0k576.0k518.0k369.0k725.0k2.9m1.3m1.1m842.0k1.3m1.9m1.8m1.8m2.1m1.3m1.6m1.0m328.0k426.0k394.0k322.0k221.0k540.0k190.0k172.0k178.0k

Depreciation and amortization

1.0k

EBIT

(437.0k)(1.1m)(431.0k)(404.0k)(345.0k)75.0k(534.0k)(2.9m)(1.1m)(974.0k)(684.0k)(1.3m)(1.9m)(1.8m)(1.8m)(2.1m)(1.2m)(1.6m)332.0k(247.0k)(429.0k)(398.0k)(322.0k)(221.0k)(490.0k)(168.0k)(172.0k)(128.0k)

EBIT margin, %

(254%)(616%)(252%)(235%)(199%)17%(280%)(16829%)(598%)(649%)(433%)(3939%)(47050%)(206000%)(1103%)(3710%)810%(419%)(980%)(764%)(256%)

Interest expense

13.0k12.0k163.0k285.0k12.0k13.0k32.0k33.0k51.0k7.0k

Interest income

1.0k

Net Income

(450.0k)(1.1m)(594.0k)(689.0k)(324.0k)62.0k(566.0k)(2.9m)(1.1m)(1.1m)(764.0k)13.5m(2.0m)(2.1m)(1.9m)(2.1m)(1.4m)(1.2m)2.1m(610.0k)(2.8m)(1.4m)324.0k(436.0k)(908.0k)1.2m(732.0k)528.0k

Manhattan Scientifics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

723.0k257.0k715.0k661.0k465.0k709.0k1.1m640.0k1.7m1.8m1.2m9.6m8.2m6.7m3.9m2.5m1.7m2.7m599.0k452.0k65.0k130.0k242.0k36.0k230.0k144.0k241.0k459.0k

Accounts Receivable

86.0k20.0k150.0k1.9m2.0m30.0k14.0k14.0k

Prepaid Expenses

150.0k199.0k154.0k90.0k108.0k87.0k128.0k70.0k93.0k4.0k169.0k3.0k7.0k6.0k2.0k17.0k12.0k6.0k18.0k12.0k

Current Assets

948.0k499.0k912.0k794.0k702.0k818.0k1.3m710.0k1.9m1.8m1.2m9.6m8.2m6.8m3.9m2.5m1.8m2.8m616.0k452.0k72.0k136.0k244.0k53.0k542.0k450.0k559.0k771.0k

PP&E

58.0k55.0k45.0k42.0k37.0k27.0k22.0k196.0k138.0k131.0k138.0k204.0k347.0k324.0k264.0k236.0k200.0k152.0k8.0k7.0k7.0k7.0k7.0k6.0k6.0k8.0k7.0k

Total Assets

2.5m2.0m2.4m2.2m2.1m2.1m2.5m2.1m3.2m2.9m2.4m17.6m16.0m14.2m11.2m9.5m8.5m9.1m15.3m14.6m8.1m7.0m6.2m2.4m1.9m3.2m1.6m2.2m

Accounts Payable

287.0k233.0k287.0k229.0k231.0k232.0k253.0k307.0k709.0k442.0k341.0k447.0k338.0k696.0k974.0k1.1m1.4m1.6m1.3m1.2m219.0k251.0k252.0k237.0k1.5m1.5m

Short-term debt

33.0k33.0k188.0k50.0k

Current Liabilities

1.3m1.1m1.8m2.1m1.9m2.1m2.0m2.5m2.2m2.1m1.9m1.8m1.9m1.2m1.4m1.6m1.9m2.0m1.4m1.3m1.7m1.9m1.7m1.9m1.9m2.0m2.2m2.2m

Long-term debt

1.0m1.2m1.4m1.5m1.6m1.7m1.7m1.8m

Non-Current Liabilities

756.0k769.0k783.0k772.0k778.0k698.0k1.7m1.4m1.4m1.5m1.6m1.7m1.7m1.8m1.9m2.0m2.1m204.0k85.0k91.0k

Total Debt

33.0k33.0k1.0m1.4m2.8m3.0m3.1m1.7m2.6m1.8m1.9m2.0m2.1m204.0k50.0k

Total Liabilities

2.1m1.9m2.6m2.8m2.7m2.8m3.7m3.9m3.6m3.6m3.4m3.5m3.6m3.0m3.4m3.6m4.0m2.2m1.4m1.3m1.7m1.9m1.7m1.9m1.9m2.0m2.3m2.3m

Common Stock

430.0k436.0k446.0k450.0k456.0k459.0k462.0k463.0k489.0k490.0k495.0k518.0k519.0k522.0k534.0k534.0k534.0k534.0k534.0k534.0k534.0k534.0k534.0k534.0k558.0k558.0k558.0k558.0k

Preferred Stock

Additional Paid-in Capital

53.8m54.7m55.3m55.6m55.9m56.2m56.4m57.5m58.6m59.4m59.8m62.1m62.3m62.7m63.3m63.5m63.5m68.2m62.5m62.5m67.3m67.3m67.3m67.3m67.6m67.6m67.6m67.6m

Retained Earnings

(53.9m)(54.9m)(56.0m)(56.7m)(57.0m)(57.4m)(58.0m)(60.9m)(60.6m)(61.6m)(62.4m)(49.7m)(51.7m)(53.8m)(57.1m)(59.2m)(60.6m)(60.1m)(50.2m)(50.8m)(62.5m)(63.9m)(64.4m)(68.4m)(69.3m)(68.1m)(69.9m)(69.4m)

Total Equity

470.0k195.0k(208.0k)(620.0k)(654.0k)(735.0k)(1.2m)(1.8m)(1.5m)(1.8m)(2.1m)13.1m11.3m10.2m6.8m4.8m3.5m5.8m12.8m12.2m5.3m4.0m3.4m(586.0k)(1.1m)102.0k(1.7m)(1.2m)

Debt to Equity Ratio

-0.8 x-1.9 x-1.7 x-1.5 x0.2 x0.2 x0.3 x0.4 x0.6 x0 x-0.1 x

Debt to Assets Ratio

0.7 x0.9 x1 x1.3 x0.2 x0.1 x0.2 x0.2 x0.2 x0 x0 x

Financial Leverage

5.4 x10.5 x-11.4 x-3.6 x-3.2 x-2.8 x-2.1 x-1.1 x-2.1 x-1.7 x-1.1 x1.3 x1.4 x1.4 x1.7 x2 x2.4 x1.6 x1.2 x1.2 x1.5 x1.8 x1.8 x-4.1 x-1.7 x31.1 x-0.9 x-1.8 x

Manhattan Scientifics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(750.0k)(1.8m)(594.0k)(1.3m)(1.6m)62.0k(504.0k)(3.4m)(1.1m)(2.2m)(2.9m)13.5m11.5m9.4m(1.9m)(4.0m)(5.3m)(1.2m)463.0k(147.0k)(2.8m)(4.2m)(4.7m)(436.0k)(1.3m)(115.0k)(732.0k)(204.0k)

Depreciation and Amortization

30.0k76.0k46.0k90.0k136.0k46.0k91.0k137.0k50.0k100.0k151.0k58.0k470.0k892.0k240.0k493.0k745.0k250.0k428.0k609.0k183.0k365.0k495.0k1.0k2.0k1.0k1.0k

Accounts Receivable

171.0k171.0k85.0k(257.0k)(237.0k)(257.0k)(150.0k)30.0k(30.0k)(30.0k)(44.0k)

Accounts Payable

16.0k(38.0k)35.0k(2.0k)(2.0k)19.0k73.0k(48.0k)57.0k(48.0k)21.0k(18.0k)339.0k157.0k388.0k730.0k237.0k(40.0k)229.0k40.0k69.0k118.0k117.0k189.0k263.0k77.0k116.0k

Cash From Operating Activities

(332.0k)(796.0k)158.0k(328.0k)(704.0k)618.0k20.0k(459.0k)(702.0k)(804.0k)(1.7m)7.1m5.9m4.5m(1.4m)(2.9m)(3.6m)(1.1m)7.6m(608.0k)(204.0k)(139.0k)(527.0k)(99.0k)(155.0k)(243.0k)(100.0k)(182.0k)

Purchases of PP&E

(2.0k)(2.0k)(19.0k)(77.0k)(242.0k)(255.0k)(13.0k)(13.0k)(23.0k)(23.0k)(8.0k)2.0k(4.0k)

Cash From Investing Activities

(2.0k)(179.0k)(2.0k)(19.0k)(77.0k)(242.0k)(255.0k)(13.0k)(13.0k)(23.0k)(8.1m)(8.0k)500.0k(2.0k)298.0k300.0k80.0k380.0k

Short-term Borrowings

(1.9m)50.0k

Cash From Financing Activities

400.0k832.0k1.0m1.0m1.2m1.8m2.0m2.4m(138.0k)2.8m50.0k

Net Change in Cash

(332.0k)(798.0k)558.0k504.0k308.0k618.0k1.0m549.0k1.1m1.2m634.0k7.0m5.7m4.1m(1.4m)(2.9m)(3.6m)1.7m(469.0k)(616.0k)(204.0k)(139.0k)(27.0k)(51.0k)143.0k57.0k(20.0k)198.0k

Interest Paid

100.0k

Income Taxes Paid

Manhattan Scientifics Ratios

USDQ2, 2011

Financial Leverage

5.4 x